tiprankstipranks
Lava Therapeutics announces initial data from Phase 1/2a study of LAVA-1207
The Fly

Lava Therapeutics announces initial data from Phase 1/2a study of LAVA-1207

LAVA Therapeutics announced initial clinical data from its ongoing Phase 1/2a study of LAVA-1207 in patients with therapy refractory metastatic castration resistant prostate cancer, mCRPC. The data are presented in a poster presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium, ASCO GU, taking place in San Francisco from February 16-18, 2023. The data presented to date show that a total of 20 patients have been treated with doses ranging from 1.5 to 120 micrograms of LAVA-1207, with treatment duration ranging from 4 to 38 weeks. The safety profile is favorable to date, without occurrence of high grade cytokine release syndrome or dose-limiting toxicities. LAVA-1207 showed predictable and linear pharmacokinetics and on-mechanism pharmacodynamics including Vgamma9Vdelta2-T cell activation. Preliminary signs of anti-tumor activity were observed at week 8, with iRECIST stable disease in 8 out of 14 evaluable patients and PSA levels stabilizing or decreasing. The largest overall decrease in PSA was 61%. The patient improved clinically with improvement in pain and fatigue.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on LVTX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles